Technical Analysis for PTN - Palatin Technologies, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| See historical PTN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 18 | MACD Bearish Signal Line Cross | Bearish | 0.00% |
| Mar 18 | 1,2,3 Pullback Bullish | Bullish Swing Setup | 0.00% |
| Mar 18 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% |
| Mar 18 | Narrow Range Bar | Range Contraction | 0.00% |
| Mar 18 | Wide Bands | Range Expansion | 0.00% |
| Mar 18 | Overbought Stochastic | Strength | 0.00% |
| Mar 15 | 1,2,3 Pullback Bullish | Bullish Swing Setup | -0.75% |
| Mar 15 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.75% |
| Mar 15 | Narrow Range Bar | Range Contraction | -0.75% |
| Mar 15 | NR7 | Range Contraction | -0.75% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-02-12
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Palatin Technologies, Inc., a biopharmaceutical company, engages in the development of peptide therapeutics for the treatment of diseases. Its drug development programs include Bremelanotide, a peptide melanocortin receptor agonist that is in Phase IIb clinical trials for the treatment of female sexual dysfunction; and PL-3994, a peptide mimetic natriuretic peptide receptor A agonist, which is in Phase I clinical trials for the treatment of cardiovascular and pulmonary indications, as well as melanocortin receptor-based compounds for treatment of obesity. The company was founded in 1986 and is based in Cranbury, New Jersey.
Chemistry Biopharmaceutical Diseases Endocrine System Molecular Biology Obesity Drug Development Peptides Female Sexual Dysfunction Therapeutics For The Treatment Of Diseases Treatment Of Obesity
Chemistry Biopharmaceutical Diseases Endocrine System Molecular Biology Obesity Drug Development Peptides Female Sexual Dysfunction Therapeutics For The Treatment Of Diseases Treatment Of Obesity
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more PTN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 1.59 |
| 52 Week Low | 0.59 |
| Average Volume | 822,341 |
| 200-Day Moving Average | 0.8986 |
| 50-Day Moving Average | 0.8131 |
| 20-Day Moving Average | 0.9418 |
| 10-Day Moving Average | 0.9983 |
| Average True Range | 0.0433 |
| ADX | 32.35 |
| +DI | 19.7225 |
| -DI | 13.0988 |
| Chandelier Exit (Long, 3 ATRs ) | 0.9101 |
| Chandelier Exit (Short, 3 ATRs ) | 0.8709 |
| Upper Bollinger Band | 1.1062 |
| Lower Bollinger Band | 0.7774 |
| Percent B (%b) | 0.65 |
| BandWidth | 34.911871 |
| MACD Line | 0.0605 |
| MACD Signal Line | 0.063 |
| MACD Histogram | -0.0025 |
| Fundamentals | Value |
|---|---|
| Market Cap | 177.7 Million |
| Num Shares | 179 Million |
| EPS | -0.08 |
| Price-to-Earnings (P/E) Ratio | -12.41 |
| Price-to-Sales | 3.03 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.02 | ||||
| Resistance 3 (R3) | 1.03 | 1.02 | 1.02 | ||
| Resistance 2 (R2) | 1.02 | 1.01 | 1.02 | 1.02 | |
| Resistance 1 (R1) | 1.01 | 1.01 | 1.01 | 1.00 | 1.01 |
| Pivot Point | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Support 1 (S1) | 0.99 | 0.99 | 0.99 | 0.98 | 0.97 |
| Support 2 (S2) | 0.98 | 0.99 | 0.98 | 0.97 | |
| Support 3 (S3) | 0.97 | 0.98 | 0.97 | ||
| Support 4 (S4) | 0.96 |
